Rationale for use mefloquine for COVID-19 treatment
Currently, the use of mefloquine in patients with COVID-19 does not have sufficient scientific justification and, given the unfavorable efficacy and safety profile, cannot be considered for routine use in clinical practice.
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Izdatelstvo OKI,
2020-10-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Currently, the use of mefloquine in patients with COVID-19 does not have sufficient scientific justification and, given the unfavorable efficacy and safety profile, cannot be considered for routine use in clinical practice. |
|---|---|
| Item Description: | 2588-0519 2618-8473 10.37489/2588-0519-2020-S4-103-105 |